References
- StanawayJDThe global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Lancet2016388 1081 108810.1016/S0140-6736(16)30579-75100695
- ZoulimFInhibition of hepatitis B virus gene expression: a step towards functional cureJ. Hepatol.20186838638810.1016/j.jhep.2017.11.036
- de NietAPeg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trialLancet Gastroenterol. Hepatol.2017257658410.1016/S2468-1253(17)30083-3
- MarcellinPHBsAg Loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trialHepatology201460294A295A10.1002/hep.27480
- NingQSwitching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)J. Hepatol.20146177778410.1016/j.jhep.2014.05.044
- LuciforaJSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNAScience20143431221122810.1126/science.1243462
- LamperticoPThe royal wedding in chronic hepatitis B: the haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapyHepatology2015611459146110.1002/hep.27731
- WangWA human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effectMAbs2016846847710.1080/19420862.2015.1134409
- LiDA potent human neutralizing antibody Fc-dependently reduces established HBV infectionselife20176e26738561456210.7554/eLife.26738
- GaoYZhangTYYuanQXiaNSAntibody-mediated immunotherapy against chronic hepatitis B virus infectionHum. Vaccin. Immunother.2017131768177310.1080/21645515.2017.13190215557221
- WenYMMuLShiYImmunoregulatory functions of immune complexes in vaccine and therapyEMBO Mol. Med.201681120113310.15252/emmm.2016065935048363
- PinceticAType I and type II Fc receptors regulate innate and adaptive immunityNat. Immunol.20141570771610.1038/ni.2939
- LiuHImmuno-potentiating pathway of HBsAg-HBIG immunogenic complex visualizedHum. Vaccin Immunother.201612778410.1080/21645515.2015.1072660
- YaoXTherapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis b patientsVaccine2007251771177910.1016/j.vaccine.2006.11.019
- TianCUse of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humansEmerg. Microbes Infect.201871610.1038/s41426-018-0034-05837134